Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute).
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis. Phase III trials for the treatment of visceral leishmaniasis had been initiated by March 2002, at which time GlaxoSmithKline hoped to file an MAA in 2003. By 1999, the compound had also undergone phase I trials in HIV-infected individuals for the treatment of Pneumocystis carinii infection. Preclinical studies have been conducted in primates and rodents for the potential treatment of Babesia microti infection.
Yeates
Clive
C
cly@welwyn11.freeserve.co.uk
D000634:Aminoquinolines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy*; D013329:Structure-Activity Relationship
D000634:Aminoquinolines; D000981:Antiprotozoal Agents; C080436:8-aminoquinoline